EGFR and non-small cell lung carcinoma: At Sun Yat-sen University, C-X-C chemokine receptor (CXCR) type 5-modified anti-EGFR CAR-T cells are evaluated in a phase I clinical trial to test their effectiveness and reliability in treating advanced NSCLC patients with EGFR mutations (NCT04153799).